NCT07522203

Brief Summary

The goal of this observational study is to learn if advanced heart pressure wave analysis (called WIA and REPA) can help track and predict clinical improvement in adults (aged 18-85) with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) who are undergoing Balloon Pulmonary Angioplasty (BPA). The main questions it aims to answer are: Do changes in these advanced heart pressure wave patterns relate to improvements in a patient's walking distance, heart function, and overall quality of life after BPA treatment? Are these new measurements more effective than standard heart pressure tests at showing how much a patient has truly improved? Participants will: Undergo standard Balloon Pulmonary Angioplasty (BPA) sessions as part of their regular medical care for CTEPH. Have their heart pressure waves recorded through a catheter during the routine BPA procedure (this does not require any extra surgical steps). Complete walking tests (6-minute walk test), blood tests, and heart ultrasounds (echocardiography) before starting the treatment and after it is completed. Fill out short surveys regarding their daily physical activity and quality of life.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
24mo left

Started Mar 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Mar 2026May 2028

Study Start

First participant enrolled

March 10, 2026

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

March 28, 2026

Completed
16 days until next milestone

First Posted

Study publicly available on registry

April 13, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2028

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2028

Last Updated

April 13, 2026

Status Verified

April 1, 2026

Enrollment Period

2.1 years

First QC Date

March 28, 2026

Last Update Submit

April 3, 2026

Conditions

Keywords

Arterial Wave EnergyHemodynamicsBalloon Pulmonary Angioplasty

Outcome Measures

Primary Outcomes (6)

  • 6 minute walking distance

    6 minute walking distance as part of standard 6MWT

    baseline, before each BPA sessions, 1 month after the last BPA session

  • NT-proBNP

    NT-proBNP level in blood

    baseline, before each BPA sessions, 1 month after the last BPA session

  • EuroQol 5-Dimension 5-Level questionnaire scores

    EQ-5D-5L (The 5-level EQ-5D version (EQ-5D-5L)) is a standardised measure of health-related quality of life developed by the EuroQol Group. Higher scores indicate better outcome. Test subsections have ratings up to 5 in 5 dimensions.

    baseline, before each BPA sessions, 1 month after the last BPA session

  • TAPSE

    Tricuspid Annular Plane Systolic Excursion (TAPSE) is an indicator of RV systolic function

    baseline, before each BPA session, 1 month after the last BPA session

  • WIA

    WIA quantifies arterial wave energy flux and identifies forward and backward compression waves (FCW, BCW) and expansion waves (FEW) within the cardiac cycle.

    baseline, periprocedural (immediately at the beginning and at the end of each BPA session)

  • REPA

    REPA decomposes the pressure waveform into reservoir pressure (Pr), representing arterial storage, and excess pressure (Pxs), representing the dynamic wave component.

    baseline, periprocedural (immediately at the beginning and at the end of each BPA session)

Study Arms (1)

Patients with CTEPH

Procedure: Balloon Pulmonary Angioplasty

Interventions

Balloon Pulmonary Angioplasty as per procedural standards

Patients with CTEPH

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study will include consecutive patients with a confirmed diagnosis of CTEPH according to current guidelines who are clinical candidates for balloon pulmonary angioplasty (BPA).

You may qualify if:

  • Age 18-85 years.
  • Confirmed diagnosis of CTEPH by a multidisciplinary CTEPH team and deemed eligible for BPA.
  • Hemodynamics compatible with pre-capillary PH according to current guidelines, as assessed by RHC (Right Heart Catheterization).
  • Technically inoperable CTEPH or persistent/recurrent PH following PEA (Pulmonary Endarterectomy).
  • Written informed consent.

You may not qualify if:

  • Predominant diagnosis of PH other than CTEPH or concomitant severe parenchymal lung disease.
  • Active infection, uncontrolled systemic disease, active malignancy, or life expectancy \< 12 months.
  • Pregnant or lactating patients.
  • Advanced renal failure (e.g., eGFR \< 30 \\text{ mL/min/1.73 m\^2}) or contraindications to contrast media (per institutional routine).
  • Inadequate image quality precluding reliable echocardiographic analysis.
  • Pressure tracings with significant artifacts hindering analysis or uncontrolled arrhythmia (e.g., atrial fibrillation with rapid ventricular response).
  • Decompensated or hemodynamically unstable patients.
  • Any other condition deemed clinically unsuitable by the investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istanbul Mehmet Akif Ersoy Educational and Training Hospital

Istanbul, 34303, Turkey (Türkiye)

RECRUITING

Related Publications (1)

  • Tas A, Alan Y, Ozcan A, Parker KH, van de Hoef T, Sezer M, Piek JJ. Ventricular-Coronary Interaction Delay is Associated With Discordance Between Fractional Flow Reserve and Coronary Flow Reserve in Intermediate Coronary Stenoses. Am J Cardiol. 2025 Aug 1;248:80-88. doi: 10.1016/j.amjcard.2025.04.003. Epub 2025 Apr 11.

    PMID: 40222466BACKGROUND

MeSH Terms

Conditions

Hypertension, Pulmonary

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesHypertensionVascular DiseasesCardiovascular Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 28, 2026

First Posted

April 13, 2026

Study Start

March 10, 2026

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

May 1, 2028

Last Updated

April 13, 2026

Record last verified: 2026-04

Locations